Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infect...
Gespeichert in:
| Veröffentlicht in: | Euro surveillance : bulletin européen sur les maladies transmissibles 2023-11, Vol.28 (47), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 47 |
| container_start_page | 1 |
| container_title | Euro surveillance : bulletin européen sur les maladies transmissibles |
| container_volume | 28 |
| creator | Rose, Angela Mc Nicolay, Nathalie Sandonis Martín, Virginia Mazagatos, Clara Petrović, Goranka Baruch, Joaquin Denayer, Sarah Seyler, Lucie Domegan, Lisa Launay, Odile Machado, Ausenda Burgui, Cristina Vaikutyte, Roberta Niessen, F Annabel Loghin, Isabela I Husa, Petr Aouali, Nassera Panagiotakopoulos, George Tolksdorf, Kristin Horváth, Judit Krisztina Howard, Jennifer Pozo, Francisco Gallardo, Virtudes Nonković, Diana Džiugytė, Aušra Bossuyt, Nathalie Demuyser, Thomas Duffy, Róisín Luong Nguyen, Liem Binh Kislaya, Irina Martínez-Baz, Iván Gefenaite, Giedre Knol, Mirjam J Popescu, Corneliu Součková, Lenka Simon, Marc Michelaki, Stella Reiche, Janine Ferenczi, Annamária Delgado-Sanz, Concepción Lovrić Makarić, Zvjezdana Cauchi, John Paul Barbezange, Cyril Van Nedervelde, Els O'Donnell, Joan Durier, Christine Guiomar, Raquel Castilla, Jesús Jonikaite, Indrė Bruijning-Verhagen, Patricia Cjl Lazar, Mihaela Demlová, Regina Wirtz, Gil Amerali, Marina Dürrwald, Ralf Kunstár, Mihály Pál Kissling, Esther Bacci, Sabrina Valenciano, Marta |
| description | IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received |
| doi_str_mv | 10.2807/1560-7917.ES.2023.28.47.2300187 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04338396v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2894462767</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-5fb3235e63324314b4188904c37960cf26568feffbcf110db4fa3b4b228d01333</originalsourceid><addsrcrecordid>eNpdks9u1DAQxiMEoqXwCsgSB1qpCf4XO-GCliXQlRatxMJeLcdxWpfEXuykqDeuPAhnjrxPnwSHXVaI04xGv_nsmfmS5DmCGS4gf4FyBlNeIp5V6wxDTGI5ozzDBEJU8HvJ8YG4_09-lDwK4RpCSmCJHyZHhJclZyw_Tn5tpFLGaqDbVqvB3GirQwDyUhobBjBfbRZvUlSCKxe2ZpCdCXIwzgJjgWzGbgjg9O77j7tvPzEEt1r6cAaa0Rt7CVa9Ud7ZtHG9sdIOQBmvxu5P-0uwSN-vNlV60Je2AZvq9WIN1rMPi5gCq4evzn8O56AavdvqcxDnRWBwU8SPkwet7IJ-so8nyae31cf5RbpcvVvMZ8tUUciGNG9rgkmuGSGYEkRrioqihFTFDTCoWsxyVrRx9lq1CMGmpq0kNa0xLhqICCEnydlO90p2YutNL_2tcNKIi9lSTLW4U1KQkt2gyJ7u2K13X0YdBtGboHTXSavdGAQuyojynE2yz_5Dr93obZxkoihlmDMeqVc7Ki4yBK_bww8QFJMfxHRhMV1YVGsx-SGWBeVi74eo8HT_zlj3ujn0_zUA-Q21Mq7_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2894462767</pqid></control><display><type>article</type><title>Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Rose, Angela Mc ; Nicolay, Nathalie ; Sandonis Martín, Virginia ; Mazagatos, Clara ; Petrović, Goranka ; Baruch, Joaquin ; Denayer, Sarah ; Seyler, Lucie ; Domegan, Lisa ; Launay, Odile ; Machado, Ausenda ; Burgui, Cristina ; Vaikutyte, Roberta ; Niessen, F Annabel ; Loghin, Isabela I ; Husa, Petr ; Aouali, Nassera ; Panagiotakopoulos, George ; Tolksdorf, Kristin ; Horváth, Judit Krisztina ; Howard, Jennifer ; Pozo, Francisco ; Gallardo, Virtudes ; Nonković, Diana ; Džiugytė, Aušra ; Bossuyt, Nathalie ; Demuyser, Thomas ; Duffy, Róisín ; Luong Nguyen, Liem Binh ; Kislaya, Irina ; Martínez-Baz, Iván ; Gefenaite, Giedre ; Knol, Mirjam J ; Popescu, Corneliu ; Součková, Lenka ; Simon, Marc ; Michelaki, Stella ; Reiche, Janine ; Ferenczi, Annamária ; Delgado-Sanz, Concepción ; Lovrić Makarić, Zvjezdana ; Cauchi, John Paul ; Barbezange, Cyril ; Van Nedervelde, Els ; O'Donnell, Joan ; Durier, Christine ; Guiomar, Raquel ; Castilla, Jesús ; Jonikaite, Indrė ; Bruijning-Verhagen, Patricia Cjl ; Lazar, Mihaela ; Demlová, Regina ; Wirtz, Gil ; Amerali, Marina ; Dürrwald, Ralf ; Kunstár, Mihály Pál ; Kissling, Esther ; Bacci, Sabrina ; Valenciano, Marta</creator><creatorcontrib>Rose, Angela Mc ; Nicolay, Nathalie ; Sandonis Martín, Virginia ; Mazagatos, Clara ; Petrović, Goranka ; Baruch, Joaquin ; Denayer, Sarah ; Seyler, Lucie ; Domegan, Lisa ; Launay, Odile ; Machado, Ausenda ; Burgui, Cristina ; Vaikutyte, Roberta ; Niessen, F Annabel ; Loghin, Isabela I ; Husa, Petr ; Aouali, Nassera ; Panagiotakopoulos, George ; Tolksdorf, Kristin ; Horváth, Judit Krisztina ; Howard, Jennifer ; Pozo, Francisco ; Gallardo, Virtudes ; Nonković, Diana ; Džiugytė, Aušra ; Bossuyt, Nathalie ; Demuyser, Thomas ; Duffy, Róisín ; Luong Nguyen, Liem Binh ; Kislaya, Irina ; Martínez-Baz, Iván ; Gefenaite, Giedre ; Knol, Mirjam J ; Popescu, Corneliu ; Součková, Lenka ; Simon, Marc ; Michelaki, Stella ; Reiche, Janine ; Ferenczi, Annamária ; Delgado-Sanz, Concepción ; Lovrić Makarić, Zvjezdana ; Cauchi, John Paul ; Barbezange, Cyril ; Van Nedervelde, Els ; O'Donnell, Joan ; Durier, Christine ; Guiomar, Raquel ; Castilla, Jesús ; Jonikaite, Indrė ; Bruijning-Verhagen, Patricia Cjl ; Lazar, Mihaela ; Demlová, Regina ; Wirtz, Gil ; Amerali, Marina ; Dürrwald, Ralf ; Kunstár, Mihály Pál ; Kissling, Esther ; Bacci, Sabrina ; Valenciano, Marta ; VEBIS hospital study team ; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above) ; I-MOVE-COVID-19 hospital study team</creatorcontrib><description>IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.</description><identifier>ISSN: 1560-7917</identifier><identifier>ISSN: 1025-496X</identifier><identifier>EISSN: 1560-7917</identifier><identifier>EISSN: 1025-496X</identifier><identifier>DOI: 10.2807/1560-7917.ES.2023.28.47.2300187</identifier><identifier>PMID: 37997665</identifier><language>eng</language><publisher>Sweden: Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</publisher><subject>Adult ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Europe - epidemiology ; Hospitalization ; Humans ; Immunization ; Immunology ; Life Sciences ; Pneumonia ; RNA, Messenger ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccine Efficacy ; Vaccinology</subject><ispartof>Euro surveillance : bulletin européen sur les maladies transmissibles, 2023-11, Vol.28 (47), p.1</ispartof><rights>Copyright Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) Nov 23, 2023</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-5fb3235e63324314b4188904c37960cf26568feffbcf110db4fa3b4b228d01333</citedby><cites>FETCH-LOGICAL-c406t-5fb3235e63324314b4188904c37960cf26568feffbcf110db4fa3b4b228d01333</cites><orcidid>0000-0003-3559-6847 ; 0000-0002-2056-1062 ; 0000-0002-4213-9209 ; 0000-0002-3405-2277 ; 0000-0002-5916-7855 ; 0000-0001-8304-5519 ; 0000-0003-4285-2116 ; 0000-0002-1327-6511 ; 0000-0002-2838-9762 ; 0000-0002-1199-4130 ; 0000-0003-4105-9669 ; 0000-0001-6316-0333 ; 0000-0001-8983-8499 ; 0000-0003-0028-4464 ; 0000-0003-3242-7247 ; 0000-0002-9190-2610 ; 0000-0002-2493-8082 ; 0000-0002-3836-0517 ; 0000-0003-0486-8491 ; 0000-0002-3797-4453 ; 0000-0001-7188-8404 ; 0000-0002-0806-3183 ; 0000-0003-0879-3554 ; 0000-0003-0489-3515 ; 0000-0002-1849-1499 ; 0000-0003-0645-5754 ; 0000-0002-7483-6703 ; 0000-0002-5992-7746 ; 0000-0001-9606-2983 ; 0000-0003-2541-1095 ; 0000-0002-6575-3439 ; 0000-0001-9952-9446 ; 0000-0002-9825-2921 ; 0000-0002-8712-6399 ; 0000-0002-6909-6923</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,861,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37997665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://u-paris.hal.science/hal-04338396$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Rose, Angela Mc</creatorcontrib><creatorcontrib>Nicolay, Nathalie</creatorcontrib><creatorcontrib>Sandonis Martín, Virginia</creatorcontrib><creatorcontrib>Mazagatos, Clara</creatorcontrib><creatorcontrib>Petrović, Goranka</creatorcontrib><creatorcontrib>Baruch, Joaquin</creatorcontrib><creatorcontrib>Denayer, Sarah</creatorcontrib><creatorcontrib>Seyler, Lucie</creatorcontrib><creatorcontrib>Domegan, Lisa</creatorcontrib><creatorcontrib>Launay, Odile</creatorcontrib><creatorcontrib>Machado, Ausenda</creatorcontrib><creatorcontrib>Burgui, Cristina</creatorcontrib><creatorcontrib>Vaikutyte, Roberta</creatorcontrib><creatorcontrib>Niessen, F Annabel</creatorcontrib><creatorcontrib>Loghin, Isabela I</creatorcontrib><creatorcontrib>Husa, Petr</creatorcontrib><creatorcontrib>Aouali, Nassera</creatorcontrib><creatorcontrib>Panagiotakopoulos, George</creatorcontrib><creatorcontrib>Tolksdorf, Kristin</creatorcontrib><creatorcontrib>Horváth, Judit Krisztina</creatorcontrib><creatorcontrib>Howard, Jennifer</creatorcontrib><creatorcontrib>Pozo, Francisco</creatorcontrib><creatorcontrib>Gallardo, Virtudes</creatorcontrib><creatorcontrib>Nonković, Diana</creatorcontrib><creatorcontrib>Džiugytė, Aušra</creatorcontrib><creatorcontrib>Bossuyt, Nathalie</creatorcontrib><creatorcontrib>Demuyser, Thomas</creatorcontrib><creatorcontrib>Duffy, Róisín</creatorcontrib><creatorcontrib>Luong Nguyen, Liem Binh</creatorcontrib><creatorcontrib>Kislaya, Irina</creatorcontrib><creatorcontrib>Martínez-Baz, Iván</creatorcontrib><creatorcontrib>Gefenaite, Giedre</creatorcontrib><creatorcontrib>Knol, Mirjam J</creatorcontrib><creatorcontrib>Popescu, Corneliu</creatorcontrib><creatorcontrib>Součková, Lenka</creatorcontrib><creatorcontrib>Simon, Marc</creatorcontrib><creatorcontrib>Michelaki, Stella</creatorcontrib><creatorcontrib>Reiche, Janine</creatorcontrib><creatorcontrib>Ferenczi, Annamária</creatorcontrib><creatorcontrib>Delgado-Sanz, Concepción</creatorcontrib><creatorcontrib>Lovrić Makarić, Zvjezdana</creatorcontrib><creatorcontrib>Cauchi, John Paul</creatorcontrib><creatorcontrib>Barbezange, Cyril</creatorcontrib><creatorcontrib>Van Nedervelde, Els</creatorcontrib><creatorcontrib>O'Donnell, Joan</creatorcontrib><creatorcontrib>Durier, Christine</creatorcontrib><creatorcontrib>Guiomar, Raquel</creatorcontrib><creatorcontrib>Castilla, Jesús</creatorcontrib><creatorcontrib>Jonikaite, Indrė</creatorcontrib><creatorcontrib>Bruijning-Verhagen, Patricia Cjl</creatorcontrib><creatorcontrib>Lazar, Mihaela</creatorcontrib><creatorcontrib>Demlová, Regina</creatorcontrib><creatorcontrib>Wirtz, Gil</creatorcontrib><creatorcontrib>Amerali, Marina</creatorcontrib><creatorcontrib>Dürrwald, Ralf</creatorcontrib><creatorcontrib>Kunstár, Mihály Pál</creatorcontrib><creatorcontrib>Kissling, Esther</creatorcontrib><creatorcontrib>Bacci, Sabrina</creatorcontrib><creatorcontrib>Valenciano, Marta</creatorcontrib><creatorcontrib>VEBIS hospital study team</creatorcontrib><creatorcontrib>Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above)</creatorcontrib><creatorcontrib>I-MOVE-COVID-19 hospital study team</creatorcontrib><title>Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022</title><title>Euro surveillance : bulletin européen sur les maladies transmissibles</title><addtitle>Euro Surveill</addtitle><description>IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.</description><subject>Adult</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Europe - epidemiology</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunology</subject><subject>Life Sciences</subject><subject>Pneumonia</subject><subject>RNA, Messenger</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccine Efficacy</subject><subject>Vaccinology</subject><issn>1560-7917</issn><issn>1025-496X</issn><issn>1560-7917</issn><issn>1025-496X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdks9u1DAQxiMEoqXwCsgSB1qpCf4XO-GCliXQlRatxMJeLcdxWpfEXuykqDeuPAhnjrxPnwSHXVaI04xGv_nsmfmS5DmCGS4gf4FyBlNeIp5V6wxDTGI5ozzDBEJU8HvJ8YG4_09-lDwK4RpCSmCJHyZHhJclZyw_Tn5tpFLGaqDbVqvB3GirQwDyUhobBjBfbRZvUlSCKxe2ZpCdCXIwzgJjgWzGbgjg9O77j7tvPzEEt1r6cAaa0Rt7CVa9Ud7ZtHG9sdIOQBmvxu5P-0uwSN-vNlV60Je2AZvq9WIN1rMPi5gCq4evzn8O56AavdvqcxDnRWBwU8SPkwet7IJ-so8nyae31cf5RbpcvVvMZ8tUUciGNG9rgkmuGSGYEkRrioqihFTFDTCoWsxyVrRx9lq1CMGmpq0kNa0xLhqICCEnydlO90p2YutNL_2tcNKIi9lSTLW4U1KQkt2gyJ7u2K13X0YdBtGboHTXSavdGAQuyojynE2yz_5Dr93obZxkoihlmDMeqVc7Ki4yBK_bww8QFJMfxHRhMV1YVGsx-SGWBeVi74eo8HT_zlj3ujn0_zUA-Q21Mq7_</recordid><startdate>20231123</startdate><enddate>20231123</enddate><creator>Rose, Angela Mc</creator><creator>Nicolay, Nathalie</creator><creator>Sandonis Martín, Virginia</creator><creator>Mazagatos, Clara</creator><creator>Petrović, Goranka</creator><creator>Baruch, Joaquin</creator><creator>Denayer, Sarah</creator><creator>Seyler, Lucie</creator><creator>Domegan, Lisa</creator><creator>Launay, Odile</creator><creator>Machado, Ausenda</creator><creator>Burgui, Cristina</creator><creator>Vaikutyte, Roberta</creator><creator>Niessen, F Annabel</creator><creator>Loghin, Isabela I</creator><creator>Husa, Petr</creator><creator>Aouali, Nassera</creator><creator>Panagiotakopoulos, George</creator><creator>Tolksdorf, Kristin</creator><creator>Horváth, Judit Krisztina</creator><creator>Howard, Jennifer</creator><creator>Pozo, Francisco</creator><creator>Gallardo, Virtudes</creator><creator>Nonković, Diana</creator><creator>Džiugytė, Aušra</creator><creator>Bossuyt, Nathalie</creator><creator>Demuyser, Thomas</creator><creator>Duffy, Róisín</creator><creator>Luong Nguyen, Liem Binh</creator><creator>Kislaya, Irina</creator><creator>Martínez-Baz, Iván</creator><creator>Gefenaite, Giedre</creator><creator>Knol, Mirjam J</creator><creator>Popescu, Corneliu</creator><creator>Součková, Lenka</creator><creator>Simon, Marc</creator><creator>Michelaki, Stella</creator><creator>Reiche, Janine</creator><creator>Ferenczi, Annamária</creator><creator>Delgado-Sanz, Concepción</creator><creator>Lovrić Makarić, Zvjezdana</creator><creator>Cauchi, John Paul</creator><creator>Barbezange, Cyril</creator><creator>Van Nedervelde, Els</creator><creator>O'Donnell, Joan</creator><creator>Durier, Christine</creator><creator>Guiomar, Raquel</creator><creator>Castilla, Jesús</creator><creator>Jonikaite, Indrė</creator><creator>Bruijning-Verhagen, Patricia Cjl</creator><creator>Lazar, Mihaela</creator><creator>Demlová, Regina</creator><creator>Wirtz, Gil</creator><creator>Amerali, Marina</creator><creator>Dürrwald, Ralf</creator><creator>Kunstár, Mihály Pál</creator><creator>Kissling, Esther</creator><creator>Bacci, Sabrina</creator><creator>Valenciano, Marta</creator><general>Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</general><general>European Centre for Disease Prevention and Control</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-3559-6847</orcidid><orcidid>https://orcid.org/0000-0002-2056-1062</orcidid><orcidid>https://orcid.org/0000-0002-4213-9209</orcidid><orcidid>https://orcid.org/0000-0002-3405-2277</orcidid><orcidid>https://orcid.org/0000-0002-5916-7855</orcidid><orcidid>https://orcid.org/0000-0001-8304-5519</orcidid><orcidid>https://orcid.org/0000-0003-4285-2116</orcidid><orcidid>https://orcid.org/0000-0002-1327-6511</orcidid><orcidid>https://orcid.org/0000-0002-2838-9762</orcidid><orcidid>https://orcid.org/0000-0002-1199-4130</orcidid><orcidid>https://orcid.org/0000-0003-4105-9669</orcidid><orcidid>https://orcid.org/0000-0001-6316-0333</orcidid><orcidid>https://orcid.org/0000-0001-8983-8499</orcidid><orcidid>https://orcid.org/0000-0003-0028-4464</orcidid><orcidid>https://orcid.org/0000-0003-3242-7247</orcidid><orcidid>https://orcid.org/0000-0002-9190-2610</orcidid><orcidid>https://orcid.org/0000-0002-2493-8082</orcidid><orcidid>https://orcid.org/0000-0002-3836-0517</orcidid><orcidid>https://orcid.org/0000-0003-0486-8491</orcidid><orcidid>https://orcid.org/0000-0002-3797-4453</orcidid><orcidid>https://orcid.org/0000-0001-7188-8404</orcidid><orcidid>https://orcid.org/0000-0002-0806-3183</orcidid><orcidid>https://orcid.org/0000-0003-0879-3554</orcidid><orcidid>https://orcid.org/0000-0003-0489-3515</orcidid><orcidid>https://orcid.org/0000-0002-1849-1499</orcidid><orcidid>https://orcid.org/0000-0003-0645-5754</orcidid><orcidid>https://orcid.org/0000-0002-7483-6703</orcidid><orcidid>https://orcid.org/0000-0002-5992-7746</orcidid><orcidid>https://orcid.org/0000-0001-9606-2983</orcidid><orcidid>https://orcid.org/0000-0003-2541-1095</orcidid><orcidid>https://orcid.org/0000-0002-6575-3439</orcidid><orcidid>https://orcid.org/0000-0001-9952-9446</orcidid><orcidid>https://orcid.org/0000-0002-9825-2921</orcidid><orcidid>https://orcid.org/0000-0002-8712-6399</orcidid><orcidid>https://orcid.org/0000-0002-6909-6923</orcidid></search><sort><creationdate>20231123</creationdate><title>Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022</title><author>Rose, Angela Mc ; Nicolay, Nathalie ; Sandonis Martín, Virginia ; Mazagatos, Clara ; Petrović, Goranka ; Baruch, Joaquin ; Denayer, Sarah ; Seyler, Lucie ; Domegan, Lisa ; Launay, Odile ; Machado, Ausenda ; Burgui, Cristina ; Vaikutyte, Roberta ; Niessen, F Annabel ; Loghin, Isabela I ; Husa, Petr ; Aouali, Nassera ; Panagiotakopoulos, George ; Tolksdorf, Kristin ; Horváth, Judit Krisztina ; Howard, Jennifer ; Pozo, Francisco ; Gallardo, Virtudes ; Nonković, Diana ; Džiugytė, Aušra ; Bossuyt, Nathalie ; Demuyser, Thomas ; Duffy, Róisín ; Luong Nguyen, Liem Binh ; Kislaya, Irina ; Martínez-Baz, Iván ; Gefenaite, Giedre ; Knol, Mirjam J ; Popescu, Corneliu ; Součková, Lenka ; Simon, Marc ; Michelaki, Stella ; Reiche, Janine ; Ferenczi, Annamária ; Delgado-Sanz, Concepción ; Lovrić Makarić, Zvjezdana ; Cauchi, John Paul ; Barbezange, Cyril ; Van Nedervelde, Els ; O'Donnell, Joan ; Durier, Christine ; Guiomar, Raquel ; Castilla, Jesús ; Jonikaite, Indrė ; Bruijning-Verhagen, Patricia Cjl ; Lazar, Mihaela ; Demlová, Regina ; Wirtz, Gil ; Amerali, Marina ; Dürrwald, Ralf ; Kunstár, Mihály Pál ; Kissling, Esther ; Bacci, Sabrina ; Valenciano, Marta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-5fb3235e63324314b4188904c37960cf26568feffbcf110db4fa3b4b228d01333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Europe - epidemiology</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunology</topic><topic>Life Sciences</topic><topic>Pneumonia</topic><topic>RNA, Messenger</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccine Efficacy</topic><topic>Vaccinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rose, Angela Mc</creatorcontrib><creatorcontrib>Nicolay, Nathalie</creatorcontrib><creatorcontrib>Sandonis Martín, Virginia</creatorcontrib><creatorcontrib>Mazagatos, Clara</creatorcontrib><creatorcontrib>Petrović, Goranka</creatorcontrib><creatorcontrib>Baruch, Joaquin</creatorcontrib><creatorcontrib>Denayer, Sarah</creatorcontrib><creatorcontrib>Seyler, Lucie</creatorcontrib><creatorcontrib>Domegan, Lisa</creatorcontrib><creatorcontrib>Launay, Odile</creatorcontrib><creatorcontrib>Machado, Ausenda</creatorcontrib><creatorcontrib>Burgui, Cristina</creatorcontrib><creatorcontrib>Vaikutyte, Roberta</creatorcontrib><creatorcontrib>Niessen, F Annabel</creatorcontrib><creatorcontrib>Loghin, Isabela I</creatorcontrib><creatorcontrib>Husa, Petr</creatorcontrib><creatorcontrib>Aouali, Nassera</creatorcontrib><creatorcontrib>Panagiotakopoulos, George</creatorcontrib><creatorcontrib>Tolksdorf, Kristin</creatorcontrib><creatorcontrib>Horváth, Judit Krisztina</creatorcontrib><creatorcontrib>Howard, Jennifer</creatorcontrib><creatorcontrib>Pozo, Francisco</creatorcontrib><creatorcontrib>Gallardo, Virtudes</creatorcontrib><creatorcontrib>Nonković, Diana</creatorcontrib><creatorcontrib>Džiugytė, Aušra</creatorcontrib><creatorcontrib>Bossuyt, Nathalie</creatorcontrib><creatorcontrib>Demuyser, Thomas</creatorcontrib><creatorcontrib>Duffy, Róisín</creatorcontrib><creatorcontrib>Luong Nguyen, Liem Binh</creatorcontrib><creatorcontrib>Kislaya, Irina</creatorcontrib><creatorcontrib>Martínez-Baz, Iván</creatorcontrib><creatorcontrib>Gefenaite, Giedre</creatorcontrib><creatorcontrib>Knol, Mirjam J</creatorcontrib><creatorcontrib>Popescu, Corneliu</creatorcontrib><creatorcontrib>Součková, Lenka</creatorcontrib><creatorcontrib>Simon, Marc</creatorcontrib><creatorcontrib>Michelaki, Stella</creatorcontrib><creatorcontrib>Reiche, Janine</creatorcontrib><creatorcontrib>Ferenczi, Annamária</creatorcontrib><creatorcontrib>Delgado-Sanz, Concepción</creatorcontrib><creatorcontrib>Lovrić Makarić, Zvjezdana</creatorcontrib><creatorcontrib>Cauchi, John Paul</creatorcontrib><creatorcontrib>Barbezange, Cyril</creatorcontrib><creatorcontrib>Van Nedervelde, Els</creatorcontrib><creatorcontrib>O'Donnell, Joan</creatorcontrib><creatorcontrib>Durier, Christine</creatorcontrib><creatorcontrib>Guiomar, Raquel</creatorcontrib><creatorcontrib>Castilla, Jesús</creatorcontrib><creatorcontrib>Jonikaite, Indrė</creatorcontrib><creatorcontrib>Bruijning-Verhagen, Patricia Cjl</creatorcontrib><creatorcontrib>Lazar, Mihaela</creatorcontrib><creatorcontrib>Demlová, Regina</creatorcontrib><creatorcontrib>Wirtz, Gil</creatorcontrib><creatorcontrib>Amerali, Marina</creatorcontrib><creatorcontrib>Dürrwald, Ralf</creatorcontrib><creatorcontrib>Kunstár, Mihály Pál</creatorcontrib><creatorcontrib>Kissling, Esther</creatorcontrib><creatorcontrib>Bacci, Sabrina</creatorcontrib><creatorcontrib>Valenciano, Marta</creatorcontrib><creatorcontrib>VEBIS hospital study team</creatorcontrib><creatorcontrib>Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above)</creatorcontrib><creatorcontrib>I-MOVE-COVID-19 hospital study team</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rose, Angela Mc</au><au>Nicolay, Nathalie</au><au>Sandonis Martín, Virginia</au><au>Mazagatos, Clara</au><au>Petrović, Goranka</au><au>Baruch, Joaquin</au><au>Denayer, Sarah</au><au>Seyler, Lucie</au><au>Domegan, Lisa</au><au>Launay, Odile</au><au>Machado, Ausenda</au><au>Burgui, Cristina</au><au>Vaikutyte, Roberta</au><au>Niessen, F Annabel</au><au>Loghin, Isabela I</au><au>Husa, Petr</au><au>Aouali, Nassera</au><au>Panagiotakopoulos, George</au><au>Tolksdorf, Kristin</au><au>Horváth, Judit Krisztina</au><au>Howard, Jennifer</au><au>Pozo, Francisco</au><au>Gallardo, Virtudes</au><au>Nonković, Diana</au><au>Džiugytė, Aušra</au><au>Bossuyt, Nathalie</au><au>Demuyser, Thomas</au><au>Duffy, Róisín</au><au>Luong Nguyen, Liem Binh</au><au>Kislaya, Irina</au><au>Martínez-Baz, Iván</au><au>Gefenaite, Giedre</au><au>Knol, Mirjam J</au><au>Popescu, Corneliu</au><au>Součková, Lenka</au><au>Simon, Marc</au><au>Michelaki, Stella</au><au>Reiche, Janine</au><au>Ferenczi, Annamária</au><au>Delgado-Sanz, Concepción</au><au>Lovrić Makarić, Zvjezdana</au><au>Cauchi, John Paul</au><au>Barbezange, Cyril</au><au>Van Nedervelde, Els</au><au>O'Donnell, Joan</au><au>Durier, Christine</au><au>Guiomar, Raquel</au><au>Castilla, Jesús</au><au>Jonikaite, Indrė</au><au>Bruijning-Verhagen, Patricia Cjl</au><au>Lazar, Mihaela</au><au>Demlová, Regina</au><au>Wirtz, Gil</au><au>Amerali, Marina</au><au>Dürrwald, Ralf</au><au>Kunstár, Mihály Pál</au><au>Kissling, Esther</au><au>Bacci, Sabrina</au><au>Valenciano, Marta</au><aucorp>VEBIS hospital study team</aucorp><aucorp>Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above)</aucorp><aucorp>I-MOVE-COVID-19 hospital study team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022</atitle><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle><addtitle>Euro Surveill</addtitle><date>2023-11-23</date><risdate>2023</risdate><volume>28</volume><issue>47</issue><spage>1</spage><pages>1-</pages><issn>1560-7917</issn><issn>1025-496X</issn><eissn>1560-7917</eissn><eissn>1025-496X</eissn><abstract>IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.</abstract><cop>Sweden</cop><pub>Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</pub><pmid>37997665</pmid><doi>10.2807/1560-7917.ES.2023.28.47.2300187</doi><orcidid>https://orcid.org/0000-0003-3559-6847</orcidid><orcidid>https://orcid.org/0000-0002-2056-1062</orcidid><orcidid>https://orcid.org/0000-0002-4213-9209</orcidid><orcidid>https://orcid.org/0000-0002-3405-2277</orcidid><orcidid>https://orcid.org/0000-0002-5916-7855</orcidid><orcidid>https://orcid.org/0000-0001-8304-5519</orcidid><orcidid>https://orcid.org/0000-0003-4285-2116</orcidid><orcidid>https://orcid.org/0000-0002-1327-6511</orcidid><orcidid>https://orcid.org/0000-0002-2838-9762</orcidid><orcidid>https://orcid.org/0000-0002-1199-4130</orcidid><orcidid>https://orcid.org/0000-0003-4105-9669</orcidid><orcidid>https://orcid.org/0000-0001-6316-0333</orcidid><orcidid>https://orcid.org/0000-0001-8983-8499</orcidid><orcidid>https://orcid.org/0000-0003-0028-4464</orcidid><orcidid>https://orcid.org/0000-0003-3242-7247</orcidid><orcidid>https://orcid.org/0000-0002-9190-2610</orcidid><orcidid>https://orcid.org/0000-0002-2493-8082</orcidid><orcidid>https://orcid.org/0000-0002-3836-0517</orcidid><orcidid>https://orcid.org/0000-0003-0486-8491</orcidid><orcidid>https://orcid.org/0000-0002-3797-4453</orcidid><orcidid>https://orcid.org/0000-0001-7188-8404</orcidid><orcidid>https://orcid.org/0000-0002-0806-3183</orcidid><orcidid>https://orcid.org/0000-0003-0879-3554</orcidid><orcidid>https://orcid.org/0000-0003-0489-3515</orcidid><orcidid>https://orcid.org/0000-0002-1849-1499</orcidid><orcidid>https://orcid.org/0000-0003-0645-5754</orcidid><orcidid>https://orcid.org/0000-0002-7483-6703</orcidid><orcidid>https://orcid.org/0000-0002-5992-7746</orcidid><orcidid>https://orcid.org/0000-0001-9606-2983</orcidid><orcidid>https://orcid.org/0000-0003-2541-1095</orcidid><orcidid>https://orcid.org/0000-0002-6575-3439</orcidid><orcidid>https://orcid.org/0000-0001-9952-9446</orcidid><orcidid>https://orcid.org/0000-0002-9825-2921</orcidid><orcidid>https://orcid.org/0000-0002-8712-6399</orcidid><orcidid>https://orcid.org/0000-0002-6909-6923</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1560-7917 |
| ispartof | Euro surveillance : bulletin européen sur les maladies transmissibles, 2023-11, Vol.28 (47), p.1 |
| issn | 1560-7917 1025-496X 1560-7917 1025-496X |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04338396v1 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Europe - epidemiology Hospitalization Humans Immunization Immunology Life Sciences Pneumonia RNA, Messenger SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccine Efficacy Vaccinology |
| title | Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T10%3A39%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccine%20effectiveness%20against%20COVID-19%20hospitalisation%20in%20adults%20(%E2%89%A5%E2%80%AF20%20years)%20during%20Omicron-dominant%20circulation:%20I-MOVE-COVID-19%20and%20VEBIS%20SARI%20VE%20networks,%20Europe,%202021%20to%202022&rft.jtitle=Euro%20surveillance%20:%20bulletin%20europ%C3%A9en%20sur%20les%20maladies%20transmissibles&rft.au=Rose,%20Angela%20Mc&rft.aucorp=VEBIS%20hospital%20study%20team&rft.date=2023-11-23&rft.volume=28&rft.issue=47&rft.spage=1&rft.pages=1-&rft.issn=1560-7917&rft.eissn=1560-7917&rft_id=info:doi/10.2807/1560-7917.ES.2023.28.47.2300187&rft_dat=%3Cproquest_hal_p%3E2894462767%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2894462767&rft_id=info:pmid/37997665&rfr_iscdi=true |